N 5984

Drug Profile

N 5984

Alternative Names: KRP-204; N-5984

Latest Information Update: 08 Feb 2010

Price : $50

At a glance

  • Originator Nisshin Pharma
  • Developer Kyorin Pharmaceutical; Nisshin Pharma
  • Class Antihyperglycaemics; Carboxylic acids; Dioxins; Obesity therapies; Small molecules
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity; Overactive bladder

Most Recent Events

  • 26 Sep 2007 Nisshin Pharma and Kyorin Pharmaceutical pass a resolution to dissolve the Nisshin-Kyorin joint venture
  • 15 May 2006 No development reported - Phase-II for Diabetes mellitus in Japan (PO)
  • 15 May 2006 Phase-II clinical trials in Obesity (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top